ADJUVANT ENDOCRINE THERAPY

Phase 2Small molecule

ADJUVANT ENDOCRINE THERAPY is one of 16 small molecule programs targeting HER2-positive Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2-Positive Breast CancerActive, not recruiting

HER2-Positive Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in HER2-Positive Breast Cancer

#DrugCompanyPhaseTrials

Tukysa

Pfizer

Approved

5 2

Herceptin

Roche

Phase 3

12 3

Perjeta

Roche

Phase 3

12 4

Taxotere

AAvyxa

Phase 3

5 5

Taxol

Teva

Phase 2

2 6

Keytruda

Merck & Co.

Phase 2

1 7

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

3 8

KN026

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

1 9

T-DM1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

5 10

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Phase 2Active, not recruiting

HER2-Positive Breast Cancer

NCT04569747

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03078751·54 enrolled

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Withdrawn· Novartis logo

Novartis·Phase 3·NCT03081234

HER2-positive Breast Cancer1 trial

20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT04569747·393 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ADJUVANT ENDOCRINE THERAPY. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADJUVANT ENDOCRINE THERAPY compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADJUVANT ENDOCRINE THERAPY. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

ADJUVANT ENDOCRINE THERAPY

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Breast Cancer2 trials

HER2-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News